Loading company…
Germany-based biopharmaceutical company developing therapies for immunology, neurology and rare diseases, founded in 2016.
UCB Innere Medizin GmbH & Co. KG researches and sells medications for chronic conditions in immunology, neurology and rare diseases, including treatments for epilepsy, Crohn's disease and rheumatoid arthritis. Founded in 2016 and based in Germany, the company is led by CEO Jean-Christophe Tellier. Its 2022 revenue was EUR 58,724,885.20 with EBITDA of EUR 6,697,749.30, and its most recent deal, on May 6, 2021, raised EUR 101 million through an IPO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at UCB Innere Medizin GmbH & Co. KG? This is my company